ABSTRACT
Backround Diagnosis of primary glial malignancies (GLI-M) in individuals presenting with Intracranial Space Occupying Lesions (ICSOL) is based on histopathological evaluation (HPE) of tissue obtained by surgical resection or biopsy with attendant resource implications and risks. Approximately 70% of ICSOLs have non-malignant etiology and distinction from malignant lesions rests largely on HPE. Furthermore, GLI-M must be differentiated from non glial malignancies and brain metastases arising from solid tumors in other organs.
Methods We describe a non-invasive test for detecting GLI-M with high sensitivity and specificity based on enrichment and identification of Circulating Glial Cells (CGCs) from peripheral blood. The performance characteristics of the test were first established in analytical validation studies. The ability of the test to detect and differentiate GLI-M from low-grade / non-malignant brain tumors (BBT), non glial type central nervous system (CNS) malignancies (NGCM), brain metastases from primary epithelial malignancies in other organs and healthy individuals was evaluated in two case control studies and two prospective studies.
Results The cumulative performance metrics of the test across all 4 clinical studies were 99.35% Sensitivity (95%CI: 96.44% - 99.98%) and 100% Specificity (95%CI: 99.37% - 100%).
Conclusions The performance characteristics of this test support its clinical utility for diagnostic triaging of individuals presenting with ICSOL and facilitating more effective diagnosis.
Competing Interest Statement
The authors Kevin O'Neill, Nelofer Syed, Timothy Crook, Sudhir Dubey, Mahadev Potharaju, Sewanti Limaye, Anantbhushan Ranade, Giulio Anichini have declared no conflicts of interest. The authors Darshana Patil, Sudha Murthy, Dadasaheb Akolkar, Pooja Fulmali, Kiran Bendale, Vineet Datta, Stefan Schuster, Shoeb Patel, Sanket Patil, Rohit Chougule, Sachin Apurwa, Pradyumna Shejwalkar, Jinumary John, Ajay Srinivasan are employees of Datar Cancer Genetics Private Limited. Rajan Datar is the founder of Datar Cancer Genetics Private Limited.
Funding Statement
This study did not receive any external funding. The entire study was funded by Datar Cancer Genetics Private Limited.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All biological samples were obtained from participants in three studies, GlioLENS with CTRI number CTRI/2019/02/017663 (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31387), TRUEBLOOD with CTRI number CTRI/2019/03/017918 (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31879) and RESOLUTE with CTRI number CTRI/2019/01/017219 (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30733). Datar Cancer Genetics Limited Institutional Ethics Committee of Datar Cancer Genetics Private Limited gave ethical approval for GlioLENS, TRUEBLOOD and RESOLUTE. Institutional Ethics Committee, Clinical Studies of Apollo Hospitals, Hyderabad gave ethical approval for GlioLENS. All participants provided their written informed consent. All studies were performed in accordance with the Declaration of Helsinki. The Imperial College Ethics Committee / Institutional Review Board gave ethical approval for the prospective study conducted at Imperial College, London.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
1. A structured abstract replaces the original unstructured abstract. 2. The Introduction and Discusison sections have been restructured. 3. Data from an addiitonal clinical study has been added. 5. Methods and Results sections have been restructured.
Data Availability
All data produced in the present work are contained in the manuscript and its supplementary file.
